The association between the gut microbiome and antituberculosis drug-induced liver injuryOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The study explored how the gut microbiome relates to anti-tuberculosis drug-induced liver injury (ADLI). Liver injury is a serious complication of tuberculosis treatment, and its microbial basis was unclear. Using a nested case-control design, researchers compared tuberculosis patients who developed liver injury with matched patients who did not. Stool samples underwent 16S ribosomal DNA sequencing before and during treatment. Mouse models tested individual and combined anti-tuberculosis drugs.
Who was studied?
The human study collected 400 faecal samples from newly diagnosed pulmonary tuberculosis patients at an infectious disease hospital in China. It included 100 liver-injury patients and 100 matched controls, each sampled before (T1) and after (T2) treatment. All patients received the same standard isoniazid, rifampicin, pyrazinamide and ethambutol regimen. The animal arm used 64 male C57BL/6 mice in eight groups, dosed by gavage for 14 days with single drugs or combinations.
What were the most important findings?
Anti-tuberculosis treatment lowered gut microbial richness and diversity in both groups, with a decline in the phylum Firmicutes and significant structural changes. Inflammatory cytokines rose markedly in the liver-injury group after treatment. Mean TNF-alpha reached 304.67 versus 164.02 in the non-injury group, IL-6 reached 15.41 versus 4.57, and IL-1beta reached 21.29 versus 12.06. Liver-injury and non-injury patients showed distinct differential genera at both time points. In mice, each drug and combination caused liver injury and its own dysbiosis pattern, including changes in Bifidobacterium.
What are the greatest implications of this study?
The work indicates that anti-tuberculosis therapy disrupts the gut microbiome and that liver injury is accompanied by specific microbial and inflammatory signatures. Depletion of beneficial short-chain fatty acid producers and expansion of opportunistic bacteria may intensify inflammation. This suggests the gut microbiome could help identify patients at risk of drug-induced liver injury. The study was single-center with an uncontrolled diet, so it shows associations. Microbiome-targeted strategies to reduce liver injury would need further testing.